Pfizer 4Q Revenue Beats; Merck’s Forecast Misses Expectations; PepsiCo Pledging to Cut Some Prices

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:
- Pfizer (PFE) reported revenue for the fourth quarter that beat the average analyst estimate.
- Merck (MRK) forecast 2026 sales and profit that missed Wall Street’s expectations as continued challenges with its HPV vaccine Gardasil, which may remain off the market in China this year, overshadowed growth from newer drugs. Full-year sales will be $65.5 billion to $67 billion, Merck said Tuesday, below the average estimate from analysts. The company expects adjusted earnings of as much as $5.15 a share. The stock fell as much as 3.2% in pre-market trading.
- Snacks and beverage company PepsiCo (PEP) reported better-than-expected fourth-quarter profit, buoyed by strong international demand, and announced a $10 billion share buyback.New York-based PepsiCo, which owns brands such as Lay’s and Gatorade, posted earnings per share of $2.26, slightly ahead of Wall Street estimates.

See omnystudio.com/listener for privacy information.